Theravance Biopharma reports Q2 EPS (28c), consensus (21c)

Reports Q2 revenue $13.7M, consensus $15.4M. Cash, cash equivalents and marketable securities totaled $167.5M as of June 30. “We are very encouraged by our team’s performance in Q2, with YUPELRI achieving good growth in both the hospital and community settings over the prior year,” said Rick E Winningham, CEO. “We are excited to capitalize on the commercial opportunity for YUPELRI, potentially enhanced near-term by PIFR-2, and realize the significant opportunity for ampreloxetine to dramatically improve the lives of MSA patients with symptomatic nOH.”